COVID-19 World

Johnson and Johnson Signs $1Billion Deal To Develop Vaccines

Washington: Johnson and Johnson announced on Wednesday that it would develop and also deliver 100 million doses of coronavirus vaccine for $1 billion deal with the United States as it stocks up vaccines to tame the pandemic.

The experimental vaccine of the company is presently under the early- stage human trials. It is expected that it will begin the advance-stage human trials in the month of September.

According to the announcement, the deal offers the US an option to order an additional 200 million doses of vaccine.

Dr. Paul Stoffels, chief science officer at Johnson & Johnson stated, “We are scaling up production in the U.S. and worldwide to deliver a SARS-CoV-2 vaccine for emergency use”.

Previously, the United States had also awarded $456 million to the Johnson and Johnson for the development of vaccines. The company said that its aim is to supply more than 1 billion doses all over the world upto 2021.

A press release issued by the US Department of Health and Human Services (HHS) said that the doses will be provided to the Americans at no cost at all if they are used in a COVID-19 vaccination campaigns.

Alex Azhar, HHS Secretary stated, “Today’s investment represents the next step in supporting Janssen’s vaccine candidate all the way through manufacturing, with the potential to bring hundreds of millions of safe and effective doses to the American people”.

Janssen Pharmaceutical Companies is developing the vaccine which is owned by the Johnson and Johnson company.

J&J is one of the few companies that has signed a deal with the U.S. for supplying their vaccines upon confederate approval.

The U.S. also announced of Friday, that it will also pay drug making companies that are Sanofi and GlaxoSmithKline upto $2.1 billion to generate as well as deliver 100 million doses of their vaccines.

Previously in the month of July, the U.S. also said that it will pay $1.95 billion to Pfizer and biotech company BioNTech for the production and delivery of vaccines if it proves to be safe and effective.

The vaccine candidate of J&J which is Ad26.COV2.S, is using the similar technology which was also used to make the experimental vaccine for Ebola virus. This vaccine was provided to people in Democratic Republic of Congo in the previous year of 2019.

About the author


Vibha Shukla

Leave a Comment